HER 2 Positive Directed Therapies in Metastatic Breast Cancer: Safety and Efficacy Considerations

Access Activity

Overview / Abstract:

Target Audience

Oncologists, oncology nurse practitioners, and oncology physician assistants.

Program Overview

Dr. Hurvitz and Dr Tolaney share key data and expert perspectives on approved and emerging HER-targeted therapies for metastatic breast cancer.

Learning Objectives

Upon completion of this educational activity, learners should be better able to:

DESCRIBE the latest clinical advances in HER-directed therapies for advanced or metastatic breast cancer
SELECT therapy for advanced or metastatic HER2-positive breast cancer according to the latest evidence and efficacy and safety data
DISCUSS available resources for caring for breast cancer patients during a global pandemic

Expiration

Feb 22, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

0.5 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

FACULTY_NAME
Sara M. Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director, Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Sponsors / Supporters / Grant Providers

AstraZeneca and Daiichi Sankyo, Inc.

Keywords / Search Terms

Relias LLC FreeCME., Relias LLC., Breast Cancer Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map